MRNA ~+12% Mon — intismeran Ph3 melanoma data set for ESMO Presidential Symposium Oct 24
Posted: Tue Sep 22, 2026 6:40 am
Biotech catalyst calendar, not just a random spike: Moderna (MRNA) jumped ~12%+ Mon toward a 52-week area high after it flagged late-breaking ESMO Congress 2026 presentations for intismeran autogene (individualized mRNA neoantigen therapy, co-developed with Merck).
Headline slot: Phase 3 INTerpath-001 (intismeran + pembrolizumab vs pembro alone in resected stage IIB–IV melanoma) in the Presidential Symposium Sat 24 Oct, 16:30 CEST / 10:30 ET (presenter Georgina V. Long). Moderna also plans an investor webcast that day (~19:00 CEST / 13:00 ET). Context: Aug topline already said the trial met RFS and DMFS endpoints — Oct 24 is the detailed data dump / Street model day.
Scalper read: “date set” rallies often front-run and then chop into the event. Liquidity in MRNA can be jumpy; mark Mon high/VWAP and whether Tue premarket holds without fresh headlines. Pair watch: MRK sympathy is usually quieter than MRNA on these prints.
Sources (paraphrase): Moderna 21 Sep ESMO abstract release / BioSpace; prior Aug Ph3 topline.
Holding MRNA into Oct 24 or treating Mon’s move as the event?
Headline slot: Phase 3 INTerpath-001 (intismeran + pembrolizumab vs pembro alone in resected stage IIB–IV melanoma) in the Presidential Symposium Sat 24 Oct, 16:30 CEST / 10:30 ET (presenter Georgina V. Long). Moderna also plans an investor webcast that day (~19:00 CEST / 13:00 ET). Context: Aug topline already said the trial met RFS and DMFS endpoints — Oct 24 is the detailed data dump / Street model day.
Scalper read: “date set” rallies often front-run and then chop into the event. Liquidity in MRNA can be jumpy; mark Mon high/VWAP and whether Tue premarket holds without fresh headlines. Pair watch: MRK sympathy is usually quieter than MRNA on these prints.
Sources (paraphrase): Moderna 21 Sep ESMO abstract release / BioSpace; prior Aug Ph3 topline.
Holding MRNA into Oct 24 or treating Mon’s move as the event?